Moxifloxacin

Dose Adult- IV or Oral = 400mg OD for 7-10 days

Indications

Acute bacterial sinusitis: Oral, I.V.: 400 mg every 24 hours for 10 days

Chronic bronchitis, acute bacterial exacerbation: Oral, I.V.: 400 mg every 24 hours for 5 days

Intra-abdominal infections, complicated: 400 mg every 24 hours for 5-14 days (initiate with I.V.); Note: 2010 IDSA guidelines recommend a treatment duration of 4-7 days (provided source controlled) for community-acquired, mild-to-moderate IAI

Pneumonia, community-acquired (including MDRSP): Oral, I.V.: 400 mg every 24 hours for 7-14 days

Skin and skin structure infections: Oral, I.V.:

Complicated: 400 mg every 24 hours for 7-21 days

Uncomplicated: 400 mg every 24 hours for 7 days

Brands

Brand Name Manufacturer Name Distributor Drug Strength Packaging Formulation Formulation Strength Price
Apdrop Ajanta Pharmaceuticals Ltd Harley's Limited 5mg 3ml eye drops per ml KES 431.00
Vigamox Alcon Pharmaceuticals Pan Pharmaceuticals Ltd 5mg 5ml eye drops per ml KES 2,430.00
Avelon Bayer Schering Pharma Bayer East Africa Ltd. 400mg 5 Tablet per tablet KES 992.73
Avelon Bayer Schering Pharma Bayer East Africa Ltd. 400mg 10 Tablet per tablet KES 1,985.07
Avelox Bayer Schering Pharma Bayer East Africa Ltd. 400mg 5 Tablet per tablet KES 1,230.37
Avelox Bayer Schering Pharma Bayer East Africa Ltd. 400mg 10 Tablet per tablet KES 2,459.40
Avelox Bayer Schering Pharma Bayer East Africa Ltd. 400mg 250ml Injection per ampoule KES 3,932.25
M-Flox Hetero Drugs Ltd Unisel Pharma (K) Ltd. 400mg 10 Tablet per tablet KES 1,390.00
Micromox Micro - Labs Limited Pharma Specialities Ltd. 400mg 15 Tablet per tablet KES 3,159.00
Maxim Jamjoom Pharma Pharma Specialities Ltd. 400mg 5 Tablet per tablet KES 1,044.00
Maxim Jamjoom Pharma Pharma Specialities Ltd. 400mg 7 Tablet per tablet KES 1,444.00
Moxicip Cipla Ltd. Surgipharm Ltd 400mg 5 Tablet per tablet KES 950.00
Moxiget Getz Pharmaceuticals Surgipharm Ltd 400mg 5 Tablet per tablet KES 1,140.00
Moxiget Getz Pharmaceuticals Surgipharm Ltd 400mg 250ml Injection per ml KES 1,587.00
Moximac Macleods Pharmaceuticals Ltd. Sai Pharmaceuticals Ltd. 400mg 5 Tablet per tablet KES 1,022.00
Moxilon Cipla Ltd. Surgipharm Ltd 400mg 5 Tablet per tablet KES 1,207.50
Moxilon Cipla Ltd. Surgipharm Ltd 4mg 100ml Injection per ml KES 1,092.50
Moxi-Bio Sava Medica Limited Eurox Pharmaceuticals Ltd. 400mg 5 Tablet per tablet KES 1,025.00
Zeebact Synermed Pharmaceuticals Ltd Saicare Enterprises Ltd. 400mg 5 Tablet per tablet KES 950.00

Moxifloxacin more information

Mode Of Action

interferes with bacterial DNA synthesis by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV.

Drug Indication E.N.T., UTI, RTI, skin and soft tissues, bone, joint, GI, intra-abdominal, pelvic and severe infections, gonorrhea.
Precautions Quinolones should be used with caution in children with a history of epilepsy or conditions that predispose to seizures, in G6PD deficiency, myasthenia gravis (risk of exacerbation). Exposure to excessive sunlight should be avoided (discontinue if photosensitivity occurs). Quinolones may induce convulsions in patients with or without a history of convulsions; taking NSAIDs at the same time may also induce them. May cause arthropathy in the weight-bearing joints of immature animals and are therefore generally not recommended in children and growing adolescents. However, the significance of this effect in humans is uncertain and in some specific circumstances short-term use of a quinolone in children is justified. Should be avoid in pregnancy and lactation.
Contra-Indications History of tendon disorders related to quinolone use, documented hypersensitivity.
Side Effects GI disturbances, dizziness, headache, tremor, confusion, convulsions, rashes, blurred vision, psychotic reactions, impaired vision, impaired taste and smell sensation, stevens-johnson syndrome, hot flushes, skin rashes, migraine, photosensitivity.
Dosage It may be given orally, or by intravenous infusion over 60 minutes. Usual dose is 400 mg once daily.
Pregnancy Category Category B3
Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals show evidence of an increased occurrence of foetal damage, the significance of which is uncertain in human